Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Interferon beta-1b via Open-House model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2028 · 642 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1b (ATC-Code nach WHO: L03AB08)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No minimum volume commitments; actual demand depends on prescribing patterns and patient numbers.

The buyer may terminate the open-house procedure early if exclusive agreements are signed, ending all non-exclusive agr...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive framework agreement for the supply of Interferon beta-1b (ATC L03AB08) to AOK PLUS insured members in Saxony and Thuringia.
  • Agreement under §130a(8) SGB V for drug discount contracts.
Afficher le résumé complet

Open-house procedure for non-exclusive pharmaceutical discount agreements for Interferon beta-1b (ATC L03AB08), organized by AOK PLUS for Saxony and Thuringia. The procedure is not a public procurement under EU directives but a voluntary transparency initiative. The framework agreement has no guaranteed volumes, no exclusivity, and runs until 31 May 2028. Submissions are accepted periodically according to a schedule provided in the project room.

Risques

No minimum volume commitments; actual demand depends on prescribing patterns and patient numbers.

The buyer may terminate the open-house procedure early if exclusive agreements are signed, ending all non-exclusive agr...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drugs.
  • Must have registered office in Germany, EU, or EEA (per §9(2) AMG).

Eligibility

  • Submit completed declarations: self-declaration on exclusion grounds and Russia sanctions declaration.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; the procedure is open-house with no competitive evaluation.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Interferon beta-1b via Open-House model

Non-exclusive framework agreement for the supply of Interferon beta-1b under §130a(8) SGB V. No minimum volume commitment. Multiple pharmaceutical entrepreneurs may participate simultaneously. The contract ends 31 May 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; the procedure is open-house with no competitive evaluation.

Détails de la procédure

Date de publication
12 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
176917-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30